CHESTERFIELD, Mo., Jul. 15, 2015 /PRNewswire-iReach/ -- Chesterfield, MO., July 15, 2015 - Orphic Therapeutics, Inc. a Missouri based pharmaceutical company has announced the closing of its first acquisition of a previously approved therapy for an orphan chronic condition that affects over 5,000 people. Terms of the transaction were not disclosed at the request of both companies.
Michelle Hefley, President and CEO of the Company, stated “This acquisition validates our business model and enables us to meet the demands of the rare chronic community with a therapy that is highly valued by patients. Our team looks forward to implementing a full array of patient services to better serve this community.”
Orphic Therapeutics, Inc. is a pharmaceutical company founded to advance pharmaceutical technologies that are FDA approved for the treatment of individuals affected by orphan diseases.
For further information: Michelle Hefley, Orphic Therapeutics,Inc., (636) 233-0600
Media Contact:Michelle Hefley, Orphic Therapeutics, Inc., 636-233-0600, mhefley@orphictherapeutics.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Orphic Therapeutics, Inc
Help employers find you! Check out all the jobs and post your resume.
